In the pivotal PULSAR and PHOTON trials, it was found to be as effective with either 12- or 16-week dosing as the original 2 mg Eylea formulation, which needs to be injected every eight weeks ...

a proposed biosimilar to EYLEA® 2 milligram (mg). AVT06 is an aflibercept biosimilar candidate for the treatment of eye disorders such as neovascular (wet) age-related macular degeneration (AMD ...

Regeneron reported that, on a combined basis, Eylea 2 mg and Eylea HD maintained their leadership position in the anti-VEGF category leader in 2024 in the United States. On a preliminary basis ...

In addition to AVT06, which is a biosimilar candidate for Eylea 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea HD 8 mg. Teva also holds commercialization ...

The safety profile of Eylea 8 mg continued to be favourable in the third year in both studies and is consistent with the well-established safety profile of Eylea 2 mg. The long-term safety data did ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.

In addition to AVT06, which is a biosimilar candidate for Eylea (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea HD (aflibercept) 8 mg. Teva also ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD).

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...